|
|
|
|
||
Re: What are the challenges....First, only 55% on average, of new NTM patients convert by six months of treatment on SOC so around 45% become refractory. Second, we already know that doctors are ignoring the Mac only part of the label so this adds 25% to the number of patients that can be treated. And, finally, Japan has already indicated to Insmed they will be using Arikayce as a front line treatment. So, by my calculation, you can take the author's numbers up about 100%. |
return to message board, top of board |